ARWR - Arrowhead Research Corp.

ARWR Stock Chart

ARWR Profile

Arrowhead Pharmaceuticals, Inc. focuses on advancing innovative treatments for challenging diseases within the United States. The company's robust pipeline includes a diverse range of RNA interference (RNAi) therapeutic candidates targeting various medical conditions. These include ARO-AAT, currently in phase II clinical trials for liver diseases associated with alpha-1 antitrypsin deficiency, and ARO-APOC3, progressing through phase 2b and phase 3 trials to address hypertriglyceridemia. Other promising candidates in Arrowhead's pipeline include ARO-ANG3 for dyslipidemia, ARO-HSD for liver diseases, and ARO-ENaC2 for cystic fibrosis-related dyslipidemia, among others.

Additionally, Arrowhead Pharmaceuticals, Inc. is actively involved in collaborations to further enhance its therapeutic portfolio. The company has established a significant partnership with Janssen Pharmaceuticals, Inc., focusing on the development of RNAi therapies like JNJ-3989 for chronic hepatitis B virus infection. Another collaboration with Takeda Pharmaceuticals U.S.A., Inc. is dedicated to advancing RNAi therapies for liver diseases. Arrowhead Pharmaceuticals, Inc. also pursues internal research initiatives such as ARO-RAGE for pulmonary conditions and ARO-MMP7 for idiopathic pulmonary fibrosis, reflecting its commitment to addressing unmet medical needs across diverse therapeutic areas.

Founded in 1989 and headquartered in Pasadena, California, Arrowhead Pharmaceuticals, Inc. continues to leverage its scientific expertise and strategic collaborations to drive innovation in RNAi-based therapies. With a strong emphasis on research and development, the company aims to deliver breakthrough treatments that offer new hope to patients facing complex and challenging diseases worldwide.

ARWR Revenue Chart

ARWR Earnings